NYSE: BSXBoston Scientific Corp Stock
$98.66+0.49 (+0.5%)
Updated Jan 17, 2025
BSX Price
$98.66
Fair Value Price
N/A
Market Cap
$145.41B
52 Week Low
$59.85
52 Week High
$99.14
P/E
80.87x
P/B
7.02x
P/S
7.76x
PEG
1.92x
Dividend Yield
N/A
Revenue
$15.91B
Earnings
$1.79B
Gross Margin
69%
Operating Margin
15.68%
Profit Margin
11.3%
Debt to Equity
0.83
Operating Cash Flow
$3B
Beta
0.87
Next Earnings
Jan 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BSX Overview
Boston Scientific Corp manufactures medical devices used in interventional radiology, interventional cardiology, peripheral interventions, and neuromodulation. It is known primarily for the development of the Taxus Stent used to open clogged arteries. With the acquisition of Cameron Health in 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (the EMBLEM subcutaneous implantable defibrillator). Boston Scientific was founded in 1979 and is headquartered in Marlborough, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BSX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
C
Momentum
B
Sentiment
B
Safety
C
Financials
B
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BSX news, forecast changes, insider trades & much more!
BSX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BSX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BSX ($98.66) is trading above its intrinsic value of $23.61, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BSX is poor value based on its earnings relative to its share price (80.87x), compared to the US market average (30.45x)
P/E vs Market Valuation
BSX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BSX due diligence checks available for Premium users.
Valuation
BSX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
80.87x
Industry
38.79x
Market
30.45x
BSX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BSX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BSX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.02x
Industry
4.13x
BSX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BSX price to earnings growth (PEG)
For valuing profitable companies with growth potential
BSX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
BSX's financial health
Profit margin
Revenue
$4.2B
Net Income
$468.0M
Profit Margin
11.1%
BSX's Earnings (EBIT) of $2.50B... subscribe to Premium to read more.
Interest Coverage Financials
BSX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.1B
Liabilities
$17.1B
Debt to equity
0.83
BSX's short-term assets ($8.76B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BSX's long-term liabilities ($11.21B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BSX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BSX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.0B
Investing
-$1.4B
Financing
$7.0M
BSX's operating cash flow ($2.94B)... subscribe to Premium to read more.
Debt Coverage Financials
BSX vs Medical Device Stocks
Boston Scientific Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.